Latest & greatest articles for breast cancer screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer screening

181. Customer fee and participation in breast-cancer screening.

Customer fee and participation in breast-cancer screening. Until 1997, breast screening by mammography was free for all women living in Turku, Finland. After this date, women born in certain years had to pay to be screened. We did a retrospective study, using data obtained from Statistics Finland, to ascertain whether or not the introduction of a fee affected attendance. We also assessed the effect of socioeconomic status on attendance. Our findings show that people who had to pay (...) for mammography attended less often than women who were entitled to free screening, irrespective of their socioeconomic status.

Lancet2001

182. Cochrane review on screening for breast cancer with mammography.

Cochrane review on screening for breast cancer with mammography. In 2000, we reported that there is no reliable evidence that screening for breast cancer reduces mortality. As we discuss here, a Cochrane review has now confirmed and strengthened our previous findings. The review also shows that breast-cancer mortality is a misleading outcome measure. Finally, we use data supplemental to those in the Cochrane review to show that screening leads to more aggressive treatment.

Lancet2001

183. Uptake of screening and prevention in women at very high risk of breast cancer.

Uptake of screening and prevention in women at very high risk of breast cancer. Management of women at high lifetime risk of familial breast cancer is hampered because of limited data concerning the appropriateness of treatment options. Over the past 8 years women at very high (>40%) lifetime risk of breast cancer have had the option of entering two chemoprevention treatment trials, a magnetic resonance imaging (MRI) breast screening study, or a risk-reducing mastectomy (RRM) study. Only 10 (...) % of eligible women have entered one of the chemotherapy trials with a similar proportion opting for RRM (>50% in mutation carriers) compared with 60% opting for MRI screening. Future chemotherapy trials will have to be designed to address this poor recruitment.

Lancet2001

184. Preventive health care 2001 update: should women be routinely taught breast self-examination to screen for breast cancer?

Preventive health care 2001 update: should women be routinely taught breast self-examination to screen for breast cancer? Preventive health care 2001 update: should women be routinely taught breast self-examination to screen for breast cancer? Preventive health care 2001 update: should women be routinely taught breast self-examination to screen for breast cancer? Baxter N, Canadian Task Force on Preventive Health Care Authors' objectives The authors' stated aim was to assess the effectiveness (...) of self-examination for breast cancer screening in women. In practice, the review focused on the effectiveness of self-examination training programmes for preventing death from breast cancer. Searching MEDLINE, PREMEDLINE, CINAHL, HealthSTAR, Current Contents and the Cochrane Library were searched from 1966 to October 2000 for English language publications describing studies in humans. The keywords used were 'breast self-examination,' 'breast diseases,' 'palpation,' 'clinical trials' and 'mass

DARE.2001

185. Effectiveness and cost-effectiveness of double reading of mammograms in breast cancer screening: findings of a systematic review

Effectiveness and cost-effectiveness of double reading of mammograms in breast cancer screening: findings of a systematic review Effectiveness and cost-effectiveness of double reading of mammograms in breast cancer screening: findings of a systematic review Effectiveness and cost-effectiveness of double reading of mammograms in breast cancer screening: findings of a systematic review Dinnes J, Moss S, Melia J, Blanks R, Song F, Kleijnen J Authors' objectives The authors' stated aim (...) was to compare the screening accuracy, patient outcomes, and costs of double reading versus single reading of mammograms for diagnosing breast cancer. In actuality, the authors focused largely on the cancer detection rates and recall rates. Searching The authors searched MEDLINE, CINAHL, DHSS Data, BIOSIS Previews, EMBASE, Cancerlit, databases on BIDS, Pascal, Dissertation Abstracts, the Cochrane Controlled Trials Register, SIGLE, HealthSTAR, Conference Papers Index, EconLit and the reference lists

DARE.2001

186. Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review

Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review Banks E Authors' objectives To investigate the relationship between use of hormone replacement therapy (HRT) and the risk of having breast cancer diagnosed between screenings (interval cancer (...) ) (sensitivity of screening) and the risk of false positive recall for screening following initial mammographic screening for breast cancer (specificity of screening). Searching MEDLINE and the Science Citation Index were searched up to 31 January 2000, with no language restrictions. No details of the search strategy were provided. The reference lists of identified papers were scanned and relevant (unspecified) journals were handsearched. Study selection Study designs of evaluations included in the review

DARE.2001

187. Preventive health care, 2001 update: screening mammography among women aged 40 - 49 years at average risk of breast cancer

Preventive health care, 2001 update: screening mammography among women aged 40 - 49 years at average risk of breast cancer Preventive health care, 2001 update: screening mammography among women aged 40 - 49 years at average risk of breast cancer Preventive health care, 2001 update: screening mammography among women aged 40 - 49 years at average risk of breast cancer Ringash J, Canadian Task Force on Preventive Health Care Authors' objectives To consider the new and updated evidence available (...) , since a review in 1994, about the effect of screening mammography on breast cancer mortality among women aged 40 to 49 years. Searching MEDLINE and Cancerlit were searched from 1966 to June 2000; the search terms were reported. Reference lists were checked for additional studies. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs), or meta-analyses including all eligible RCTs, were eligible for inclusion in the section on the effectiveness

DARE.2001

188. Strategies for increasing women participation in community breast cancer screening.

Strategies for increasing women participation in community breast cancer screening. BACKGROUND: Strategies for reducing breast cancer mortality in western countries have focused on screening, at least for women aged 50 to 69 years. One of the requirements of any community screening program is to achieve a high participation rate, which is related to methods of invitation. Therefore, it was decided to systematically review the scientific evidence on the different strategies aimed at improving (...) women's participation in breast cancer screening programs and activities. OBJECTIVES: To assess the effectiveness of different strategies for increasing the participation rate of women invited to community (population-based) breast cancer screening activities or mammography programs. SEARCH STRATEGY: MEDLINE (1966-2000), CENTRAL (2000), and EMBASE (1998-1999) searches for 1966 to 1999 were supplemented by reports and letters to the European Screening Breast Cancer Programs (Euref Network). SELECTION

Cochrane2001

189. Screening for breast cancer with mammography.

Screening for breast cancer with mammography. BACKGROUND: Mammographic screening for breast cancer is controversial, as reflected in greatly varying national policies. OBJECTIVES: To assess the effect of screening for breast cancer with mammography on mortality and morbidity. SEARCH STRATEGY: MEDLINE (16 May 2000), The Cochrane Breast Cancer Group's trial register (24 Jan 2000) and reference lists. Letters, abstracts and unpublished trials. Authors were contacted. SELECTION CRITERIA: Randomised (...) is 0.80 (95% CI 0.71-0.89). However, breast cancer mortality is considered to be an unreliable outcome and biased in favour of screening. Flaws are due to differential exclusion of women with breast cancer from analysis and differential misclassification of cause of death. REVIEWER'S CONCLUSIONS: The currently available reliable evidence does not show a survival benefit of mass screening for breast cancer (and the evidence is inconclusive for breast cancer mortality). Women, clinicians and policy

Cochrane2001

190. [The effects of extending the use of mammography screening: a report on the cost-effectiveness of breast cancer screening in 60 to 69 year-old women]

[The effects of extending the use of mammography screening: a report on the cost-effectiveness of breast cancer screening in 60 to 69 year-old women] Rintasyopaseulonnan laajentamisen vaikutukset - Selvitys mammografiaan perustuvan rintasyopaseulonnan kustannus-vaikuttavuudesta 60-69 -vuotiailla naisilla [The effects of extending the use of mammography screening: a report on the cost-effectiveness of breast cancer screening in 60 to 69 year-old women] Rintasyopaseulonnan laajentamisen (...) vaikutukset - Selvitys mammografiaan perustuvan rintasyopaseulonnan kustannus-vaikuttavuudesta 60-69 -vuotiailla naisilla [The effects of extending the use of mammography screening: a report on the cost-effectiveness of breast cancer screening in 60 to 69 year-old women] Saarenmaa I, Salminen T, Varonen H, Fredriksson M, Sintonen H, Makela M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has

Health Technology Assessment (HTA) Database.2000

191. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How?

Does this patient have breast cancer? The screening clinical breast examination: should it be done? How? Does this patient have breast cancer? The screening clinical breast examination: should it be done? How? Does this patient have breast cancer? The screening clinical breast examination: should it be done? How? Barton M B, Harris R, Fletcher S W Authors' objectives To collect evidence on the effectiveness of clinical breast examination (CBE) in screening for breast cancer, and information (...) was compared For data on the test characteristics of screening CBE, the included studies had to confirm all breast cancer diagnoses histologically. The breast cancer outcome for all screens had to be determined within a defined follow-up period. Participants included in the review No inclusion criteria relating to the study population were specified. The included studies were mostly of women aged 40 to 64 years (a few studies included in the review include younger and older women). For test characteristics

DARE.1999

192. A study on the cost effectiveness of sestamibi scintimammography for screening women with dense breasts for breast cancer

A study on the cost effectiveness of sestamibi scintimammography for screening women with dense breasts for breast cancer A study on the cost effectiveness of sestamibi scintimammography for screening women with dense breasts for breast cancer A study on the cost effectiveness of sestamibi scintimammography for screening women with dense breasts for breast cancer Allen M W, Hendi P, Bassett L, Phelps M E, Gambhir S S Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Sestamibi scintimammography for screening women with dense breasts for breast cancer. As a nuclear medicine technique, this procedure is based on the enhanced uptake of sestamibi in tumours in the breast and elsewhere. Type of intervention Screening. Economic study

NHS Economic Evaluation Database.1999

193. Breast cancer screening by mammography in Norway: is it cost-effective?

Breast cancer screening by mammography in Norway: is it cost-effective? Breast cancer screening by mammography in Norway: is it cost-effective? Breast cancer screening by mammography in Norway: is it cost-effective? Norum J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) conclusions A 30% reduction in breast cancer death was calculated from this survey. Modelling A model was used to estimate the costs and future benefits of screening although the details of the model employed were not given. The description of the non-screening strategy was based on national data on assessment and treatment. Outcomes assessed in the review The following outcomes were assessed from a review of the literature: frequency of stage I and II breast cancers, median life expectancy for women aged

NHS Economic Evaluation Database.1999

194. 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening.

14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening. 10371567 1999 07 08 1999 07 08 2016 11 24 0140-6736 353 9168 1999 Jun 05 Lancet (London, England) Lancet 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening. 1903-8 The Edinburgh randomised trial of breast-cancer screening recruited women aged 45-64 years from 1978 to 1981 (cohort 1), and those aged 45-49 years during 1982-85 (cohorts 2 and 3). Results based on 14 years (...) of follow-up and 270,000 woman-years of observation are reported. Breast-cancer mortality rates in the intervention group (28,628 women offered screening) were compared with those in the control group (26,026) with adjustment for socioeconomic status (SES) of general medical practices. Rate ratios were derived by means of logistic regression for the total trial population and for women first offered screening while younger than 50 years. Analyses were by intention to treat. Initial unadjusted results

Lancet1999

195. Use of a mathematical model to evaluate breast cancer screening policy

Use of a mathematical model to evaluate breast cancer screening policy Use of a mathematical model to evaluate breast cancer screening policy Use of a mathematical model to evaluate breast cancer screening policy Baker R D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology Breast cancer screening. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population Women aged 50-65 screened for breast cancer in the United Kingdom. Setting The effectiveness data used in the study were derived from three screening centres in Manchester, Wigan and Bolton in the United Kingdom. The economic analysis was performed in the United Kingdom. Dates to which data relate Effectiveness data were derived during the period

NHS Economic Evaluation Database.1998

196. The costs of treating breast cancer in the United Kingdom: implications for screening

The costs of treating breast cancer in the United Kingdom: implications for screening The costs of treating breast cancer in the United Kingdom: implications for screening The costs of treating breast cancer in the United Kingdom: implications for screening Wolstenholme J L, Smith S J, Whynes D K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Screening for breast cancer. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population The treatment cost analysis was based on the case notes of 137 breast cancer patients. 102 patients had stage 1 cancer, 13 stage 2, 16 stage 3 and 6 had stage 4 cancer. This information was used to determine the screening scenario for the 2,687 new breast

NHS Economic Evaluation Database.1998

197. Efficacy of reverse transcriptase-polymerase chain reaction screening for micrometastatic disease in axillary lymph nodes of breast cancer patients

Efficacy of reverse transcriptase-polymerase chain reaction screening for micrometastatic disease in axillary lymph nodes of breast cancer patients Efficacy of reverse transcriptase-polymerase chain reaction screening for micrometastatic disease in axillary lymph nodes of breast cancer patients Efficacy of reverse transcriptase-polymerase chain reaction screening for micrometastatic disease in axillary lymph nodes of breast cancer patients Lockett M A, Metcalf J S, Baron P L, O'Brien P H (...) , Elliott B M, Robison J G, Cole D J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Reverse transcriptase-polymerase chain reaction (RT-PCR) screening for micrometastatic disease in axillary lymph nodes of breast cancer patients. Type

NHS Economic Evaluation Database.1998

198. Efficacy of breast-cancer screening for female relatives of breast-cancer-index cases: Taiwan multicentre cancer screening (TAMCAS)

Efficacy of breast-cancer screening for female relatives of breast-cancer-index cases: Taiwan multicentre cancer screening (TAMCAS) Efficacy of breast-cancer screening for female relatives of breast-cancer-index cases: Taiwan multicentre cancer screening (TAMCAS) Efficacy of breast-cancer screening for female relatives of breast-cancer-index cases: Taiwan multicentre cancer screening (TAMCAS) Lai M S, Yen M F, Kuo H S, Koong S L, Chen T H, Duffy S W Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technology investigated was breast cancer screening female relatives of breast -cancer index cases using mammography. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population

NHS Economic Evaluation Database.1998

199. Mammography screening as a method for the early detection of breast cancer

Mammography screening as a method for the early detection of breast cancer Mammography screening as a method for the early detection of breast cancer Mammography screening as a method for the early detection of breast cancer Gibis B, Busse R, Reese E, Richter K, Schwartz FW, Koebberling J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Gibis B, Busse R, Reese E, Richter K, Schwartz FW, Koebberling J. Mammography screening as a method for the early detection of breast cancer. German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA@ DIMDI). 1998 Authors' objectives This report aims to answer the following questions: - To what extent are reductions in the efficacy of a mammography screening programme with a participation rate of under 70% to be tolerated? - What quality

Health Technology Assessment (HTA) Database.1998

200. Economic evaluation of a mammography-based breast cancer screening programme in Spain

Economic evaluation of a mammography-based breast cancer screening programme in Spain Economic evaluation of a mammography-based breast cancer screening programme in Spain Economic evaluation of a mammography-based breast cancer screening programme in Spain Garuz R, Forcen T, Cabases J, Antonanzas F, Trinxet C, Rovira J, Anton F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A mammography-based breast cancer screening programme. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population The study population comprised women between 50 and 65 years of age. Setting Secondary care. The study was carried out in Spain. Dates to which data relate The data for the effectiveness

NHS Economic Evaluation Database.1997